Table 1.
Estimates of incidence of PI-IBS1
| Author | Study type | Control group | Type of exposure | Follow-up (mo) | Criteria for diagnosis of IBS | Mean quality assessment score | Incidence of IBS in exposed cohort | Country |
| McKendrick[24] | Prospective | None | Confirmed Salmonella | 12 | Rome I | 14.5 | 12/38 = 31.6% | United Kingdom |
| Neal[13] | Prospective | None | Confirmed-bacterial GE | 6 | Modified Rome I | 16.0 | 23/366 = 6.3% | United Kingdom |
| Gwee[22] | Prospective | None | Confirmed gastroenteritis | 6 | Clinical assessment | 21.0 | 9/86 = 10.5% | United Kingdom |
| Gwee[28] | Prospective | None | Confirmed Shigella, Campylobacter, Salmonella | 12 | Rome I | 21.5 | 22/109 = 20.2% | United Kingdom |
| Rodríguez[6] | Prospective | Matched from database | Confirmed bacterial GE | 12 | Physician diagnosis | 19.0 | 14/318 = 4.4% | United Kingdom |
| Ilnyckyj[5] | Prospective | Uninfected contemporaneous | Self reported (traveler’s diarrhea) | 3 | Rome I | 22.5 | 2/48 = 4.2% | Canada |
| Dunlop[3] | Prospective | None | Self reported (presumed Campylobacter) | 3 | Rome I | 21.0 | 103/747 = 13.8% | United Kingdom |
| Parry[27] | Prospective Case control | Matched from database | Confirmed Campylobacter, Salmonella | 3-6 | Rome II | 23.5 | 18/128 = 14.1% | United Kingdom |
| Wang[12] | Prospective | Uninfected family | Confirmed Shigella | 12, 24 | Rome II | 23.5 | 24/295 = 8.1% | China |
| Okhuysen[15] | Prospective | None | Self-reported travelers’ diarrhea | 6 | Rome II | 20.0 | 6/169 = 3.6% | United States |
| Kim[4], Ji[23], Jung[41] | Prospective | Uninfected contemporaneous | Self reported (presumed Shigella) | 12, 36, 60 | Modified Rome I & II | 24.5 | 15/143 = 10.5% | South Korea |
| Mearin[25] | Prospective | Uninfected contemporaneous | Self reported (presumed Salmonella) | 3, 6, 12 | Rome II | 22.5 | 27/467 = 5.8% | Spain |
| Marshall[11] | Prospective | Uninfected contemporaneous | Self reported (presumed E. coli, Campylobacter) | 24-36 | Rome I | 26.5 | 417/1368 = 30.5% | Canada |
| Borgaonkar[21] | Prospective | None | Confirmed (any bacterial pathogen) | 3 | Manning & Rome I | 20.0 | 7/191 = 3.7% | Canada |
| Moss-Morris[26] | Prospective | Mononucleosis | Confirmed Campylobacter | 3, 6 | Rome I & II | 21.5 | 59/592 = 10.0% | New Zealand |
| Stermer[14] | Prospective | Uninfected contemporaneous | Self reported (travelers’ diarrhea) | 6 | Rome II | 13.6 | 13/118 = 11.0% | Israel |
| Marshall[10] | Prospective | Uninfected contemporaneous | Self reported (presumed viral) | 3, 6, 12, 24 | Rome I | 23.5 | 15/92 = 16.3% | Canada |
| Spence[30] | Prospective | None | Confirmed Campylobacter | 3, 6 | Rome I & II | 24.0 | 63/620 = 10.2% | New Zealand |
1
Thabane et al. APT 2007; 26: 535-544.